Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis

Tappeiner, Christoph; Rath, Thomas; Heiligenhaus, Arnd (2018). Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis. Klinische Monatsblätter für Augenheilkunde, 235(5), pp. 562-567. Ferdinand Enke Verlag 10.1055/a-0586-3931

Text a-0586-3931.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (103kB) | Request a copy

The first-line therapy of uveitis normally consists of topical and/or systemic corticosteroid use. To achieve long-term ocular quiescence, to prevent uveitic secondary complications, to allow corticosteroid sparing and to avoid corticosteroid-related adverse effects, the application of immunosuppressive drugs (disease modifying antirheumatic drugs; DMARDs) is often necessary during the course of the disease. This article presents a structural overview of the most important conventional synthetic DMARDs, their indication, adverse events and interdisciplinary monitoring.

Interest & Impact

Downloads

1 since deposited on 31 Jan 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item